XML 26 R4.htm IDEA: XBRL DOCUMENT v3.23.3Close
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 2,287.9 $ 3,419.3
Marketable securities 0.0 1,473.5
Inventory 2,982.4 1,344.4
Other current assets 974.1 1,417.6
Total current assets 8,454.1 9,791.2
Marketable securities 0.1 705.7
Property, plant and equipment, net 3,301.6 3,298.6
Operating lease assets 460.9 403.9
Intangible assets, net 7,344.6 1,850.1
Goodwill 6,807.5 5,749.0
Deferred tax asset 1,069.8 1,226.4
Investments and other assets 754.6 1,529.2
Total assets 28,193.2 24,554.1 Close
Current liabilities:    
Current portion of term loan 500.0 0.0
Taxes payable 243.8 259.9
Accounts payable 440.1 491.5
Accrued expense and other 3,838.4 2,521.4
Total current liabilities 5,022.3 3,272.8
Notes payable and term loan 6,786.4 6,281.0
Deferred tax liability 728.1 334.7
Long-term operating lease liabilities 428.8 333.0
Other long-term liabilities 747.9 944.2
Total liabilities 13,713.5 11,165.7 Close
Commitments, contingencies and guarantees
Biogen Idec Inc. shareholders' equity    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 242.2 73.3
Accumulated other comprehensive income (loss) (159.3) (164.9)
Retained earnings 17,377.9 16,466.5
Treasury stock, at cost (2,977.1) (2,977.1)
Total Biogen Inc. shareholders’ equity 14,483.8 13,397.9 Close
Noncontrolling interests (4.1) (9.5)
Total equity 14,479.7 13,388.4
Total liabilities and equity 28,193.2 24,554.1
Nonrelated Party    
Current assets:    
Accounts receivable, net 1,781.4 1,705.0
Related Party    
Current assets:    
Accounts receivable, net $ 428.3 $ 431.4